title: Dosimetric quality endpoints for low-dose-rate prostate brachytherapy using biological effective dose (BED) vs. conventional dose.
abstract: The purpose of this study was to compare conventional low-dose-rate prostate brachytherapy dosimetric quality parameters with their biological effective dose (BED) counterparts. To validate a model for transformation from conventional dose to BED, the postimplant plans of 31 prostate brachytherapy patients were evaluated using conventional dose-volume histogram (DVH) quality endpoints and analogous BED-DVH endpoints. Based on CT scans obtained 4 weeks after implantation, DVHs were computed and standard dosimetric endpoints V100 (volume receiving 100% of the prescribed dose), V150, V200, HI (1-[V150/V100]), and D90 (dose that 90% of the target volume received) were obtained for quality analysis. Using known and reported transformations, dose grids were transformed to BED-early (alpha/beta = 10 Gy) and BED-late (alpha/beta = 3 Gy) grids, and the same dosimetric endpoints were analyzed. For conventional, BED-early and BED-late DVHs, no differences in V100 were seen (0.896, 0.893, and 0.894, respectively). However, V150 and V200 were significantly higher for both BED-early (0.582 and 0.316) and BED-late (0.595 and 0.337), compared with the conventional (0.539 and 0.255) DVHs. D90 was significantly lower for the BED-early (103.1 Gy) and BED-late transformations (106.9 Gy) as compared with the conventional (119.5 Gy) DVHs. The conventional prescription parameter V100 is the same for the corresponding BED-early and BED-late transformed DVHs. The toxicity parameters V150 and V200 are slightly higher using the BED transformations, suggesting that the BED doses are somewhat higher than predicted using conventional DVHs. The prescription/quality parameter D90 is slightly lower, implying that target coverage is lower than predicted using conventional DVHs. This methodology can be applied to analyze BED dosimetric endpoints to improve clinical outcome and reduce complications of prostate brachytherapy.
authors.affiliation: Department of Radiation and Cellular Oncology, University of Chicago Hospitals, Chicago, IL 60637, USA.
authors.forename: Rachana
authors.initials: R
authors.lastname: Singh
authors.forename: Hania
authors.initials: H
authors.lastname: Al-Hallaq
authors.forename: Charles A
authors.initials: CA
authors.lastname: Pelizzari
authors.forename: Gregory P
authors.initials: GP
authors.lastname: Zagaja
authors.forename: Andrew
authors.initials: A
authors.lastname: Chen
authors.forename: Ashesh B
authors.initials: AB
authors.lastname: Jani
mesh_terms: D001918:Brachytherapy; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D012062:Relative Biological Effectiveness